Xenleta

Chemical Namelefamulin
Dosage FormInjectable (intravenous; 150 mg/15 mL of 0.9% sodium chloride); tablet (oral; 600 mg)
Drug ClassAntibacterials
SystemRespiratory
CompanyNabriva
Approval Year2019

Indication

  • Xenleta is indicated for the treatment of adults with community-acquired bacterial pneumonia (CABP) caused by susceptible microorganisms.
Last updated on 10/29/2020

More on this drug: Clinical Trials

Have we missed a study, or would you like to comment on a study?

Document TitleYearSource
Xenleta (lefamulin) Prescribing Information 2019Nabriva